Abiraterone
Information
- Drug Name
- Abiraterone
- Description
- Entry(CIViC)
- 1
CIViC
| Disease | Mutation | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| prostate cancer | AR SPLICE VARIANT 7 AR SPLICE VARIANT 7 | B |
Predictive
|
Supports
|
Resistance |
N/A
|
3 | 25184630 | Detail |
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| Detection of AR-V7 in circulating tumor cells of 6... | AR | AR SPLICE VARIANT 7 AR SPLICE VARIANT 7 | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04262154 | Active, not recruiting | Phase 2 | Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer | March 3, 2020 | September 2026 |
| NCT02366494 | Active, not recruiting | Micro RNAs to Predict Response to Androgen Deprivation Therapy | April 29, 2015 | June 2025 | |
| NCT04207255 | Active, not recruiting | Phase 2 | Addition of Opaganib to Androgen Antagonists in Patients With mCRPC | March 27, 2020 | May 31, 2024 |
| NCT04034095 | Active, not recruiting | A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan | July 8, 2019 | October 8, 2025 | |
| NCT03934840 | Active, not recruiting | Phase 2 | CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone | October 10, 2019 | May 2025 |
| NCT02772588 | Active, not recruiting | Phase 2 | AASUR in High Risk Prostate Cancer | May 2016 | May 2026 |
| NCT01949337 | Active, not recruiting | Phase 3 | Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer | January 22, 2014 | August 31, 2024 |
| NCT01961843 | Active, not recruiting | N/A | Abiraterone Acetate for Castrate Resistant Prostate Cancer | October 2013 | December 31, 2024 |
| NCT06060587 | Active, not recruiting | Phase 2 | Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone | October 19, 2023 | December 22, 2030 |
| NCT05084859 | Active, not recruiting | Phase 1 | A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors | November 3, 2021 | July 2026 |
| NCT03141671 | Active, not recruiting | Phase 2 | Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509) | November 24, 2017 | December 31, 2025 |
| NCT03860987 | Active, not recruiting | Phase 2 | Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer | April 30, 2019 | August 1, 2028 |
| NCT03511196 | Active, not recruiting | Early Phase 1 | Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer | September 17, 2018 | June 2024 |
| NCT05288166 | Active, not recruiting | Phase 3 | A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) | April 14, 2022 | October 2027 |
| NCT00268476 | Active, not recruiting | Phase 2/Phase 3 | Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy | July 8, 2005 | December 2030 |
| NCT04666129 | Active, not recruiting | Phase 1 | Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer | February 18, 2021 | May 29, 2024 |
| NCT04647526 | Active, not recruiting | Phase 3 | Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment | February 25, 2021 | March 2028 |
| NCT03414034 | Completed | Phase 2 | Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer | June 18, 2018 | October 16, 2023 |
| NCT03418324 | Completed | Phase 2 | Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy | March 5, 2018 | November 6, 2019 |
| NCT02043678 | Completed | Phase 3 | Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms | March 30, 2014 | February 8, 2024 |
| NCT00924469 | Completed | Phase 2 | A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone Acetate in Male Participants With Prostate Cancer | November 2009 | March 2012 |
| NCT01424930 | Completed | Phase 2 | A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate Cancer | October 2011 | May 2013 |
| NCT01485861 | Completed | Phase 1/Phase 2 | Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy | January 11, 2012 | August 31, 2022 |
| NCT01553188 | Completed | Phase 2 | AMG 386 and Abiraterone for Advanced Prostate Cancer | February 8, 2012 | July 1, 2018 |
| NCT01574937 | Completed | Phase 1 | XL-184+Abiraterone in Post-Chemo CRPC | April 3, 2012 | July 1, 2021 |
| NCT01756638 | Completed | Phase 2 | A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer | June 6, 2012 | October 17, 2014 |
| NCT01780220 | Completed | Phase 1/Phase 2 | Radiotherapy Plus Hormone Therapy in Biochemically-relapsing Prostate Cancer Patients Following Surgery | December 2012 | January 7, 2022 |
| NCT01795703 | Completed | Phase 2 | A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel | June 2012 | October 2014 |
| NCT01972217 | Completed | Phase 2 | Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer. | April 1, 2014 | August 24, 2023 |
| NCT01995513 | Completed | Phase 4 | Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients | October 22, 2013 | August 31, 2022 |
| NCT02789878 | Completed | Phase 2 | Neoadjuvant Androgen Deprivation Therapy Plus Abiraterone With or Without Apalutamide for High-Risk Prostate Cancer | January 24, 2019 | August 1, 2022 |
| NCT02867020 | Completed | Phase 2 | Study of Abiraterone Acetate Plus ADT Versus APALUTAMIDE Versus Abiraterone and APALUTAMIDE in Patients With Advanced Prostate Cancer With Non-castrate Testosterone Levels | October 11, 2017 | June 30, 2021 |
| NCT02883166 | Completed | Phase 1 | Improving Bio-availability of the Expensive Oral Oncolytic Drug Abiraterone by Food Intake | August 2016 | March 2019 |
| NCT03072238 | Completed | Phase 3 | Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer | June 30, 2017 | April 24, 2024 |
| NCT03295565 | Completed | Phase 2/Phase 3 | Optimal Sequencing of Treatment Options for Poor Risk mCRPC Previously Treated With Docetaxel | May 7, 2017 | March 2, 2022 |
| NCT03298087 | Completed | Phase 2 | Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer | July 1, 2018 | March 31, 2024 |
| NCT03896984 | Completed | Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo). | March 18, 2019 | December 14, 2020 | |
| NCT04087174 | Completed | Phase 1 | A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer | August 5, 2019 | June 22, 2021 |
| NCT04179396 | Completed | Phase 1 | Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP) | December 5, 2019 | January 18, 2023 |
| NCT04628988 | Completed | Phase 1 | A Study of CC-90011 and Comparators in Participants With Prostate Cancer | July 28, 2021 | May 26, 2023 |
| NCT05701007 | Completed | Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland | February 13, 2023 | April 10, 2024 | |
| NCT05733351 | Recruiting | Phase 1 | Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer | August 3, 2023 | December 16, 2027 |
| NCT05751941 | Recruiting | Phase 2 | Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer | February 14, 2023 | October 2025 |
| NCT04175431 | Recruiting | Phase 2 | Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study | September 30, 2020 | July 1, 2029 |
| NCT04221542 | Recruiting | Phase 1 | Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer | March 4, 2020 | July 30, 2028 |
| NCT06173362 | Recruiting | Phase 2 | Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer | November 9, 2023 | May 2027 |
| NCT04748042 | Recruiting | Phase 2 | Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON) | May 28, 2021 | May 2025 |
| NCT05376722 | Recruiting | Phase 2 | A Study of Pamiparib Combined With Abiraterone Acetate in Neoadjuvant Treatment of Prostate Cancer | February 22, 2022 | September 2024 |
| NCT06378866 | Recruiting | Phase 2 | Stereotactic Body Radiation Therapy Plus Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy for Treatment of Metastatic, Recurrent Hormone-Sensitive Prostate Cancer, DIVINE Trial | June 3, 2024 | May 31, 2029 |
| NCT03678025 | Recruiting | Phase 3 | Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer | September 24, 2018 | October 1, 2031 |
| NCT05361915 | Suspended | Phase 2 | Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer | September 2025 | January 2028 |
| NCT02125617 | Terminated | Urokinase Plasminogen Activator Receptor in Abiraterone Treated Patients With Castration Resistant Prostate Cancer | January 2014 | February 2017 | |
| NCT04726332 | Terminated | Phase 1 | Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) | February 10, 2021 | May 2, 2024 |
| NCT02758132 | Terminated | Phase 2 | Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases | March 1, 2016 | September 6, 2016 |
| NCT04631601 | Terminated | Phase 1/Phase 2 | Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC) | January 15, 2021 | October 23, 2023 |
| NCT01995058 | Terminated | Phase 2 | Study of Cabozantinib in Combination With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer | December 2013 | November 2014 |
| NCT01828476 | Terminated | Phase 2 | Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer | June 2013 | March 3, 2016 |
| NCT02711137 | Terminated | Phase 1/Phase 2 | Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies | May 18, 2016 | February 13, 2019 |
| NCT03150056 | Terminated | Phase 1 | Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer | July 18, 2017 | June 22, 2021 |
| NCT03878524 | Terminated | Phase 1 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | April 1, 2020 | December 10, 2020 |
| NCT01741753 | Terminated | Phase 1 | BKM120+Abiraterone Acetate for Metastatic CRPC | November 2012 | September 1, 2016 |
| NCT05188911 | Unknown status | Analysis of Next Generation PET and Liquid Biopsy to Monitor mCRPC Treated With Abiraterone: ANGELA Trial | July 15, 2020 | July 15, 2022 | |
| NCT04839055 | Unknown status | Phase 1/Phase 2 | The Effects of Coenzyme A Combined With Abiraterone on Patients With CRPC | March 18, 2021 | May 2021 |
| NCT02254785 | Unknown status | Phase 2 | Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer | October 2014 | May 2020 |
| NCT02049190 | Unknown status | Phase 1/Phase 2 | Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer | February 2014 | December 2017 |
| NCT03173859 | Withdrawn | Phase 2 | Efficacy of Rotations Between Abiraterone Acetate and Apalutamide in mCRPC Patients | January 2018 | December 31, 2020 |
| NCT02380313 | Withdrawn | Phase 1 | Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide or Aibraterone | October 2015 | May 2017 |
| NCT05705700 | Withdrawn | Phase 2 | Biomarker Study of in Men With PSA Progression on Abi for CR or CS PC (Bio-STAMP) | February 2023 | January 2030 |